Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Federica Sora', Marino Gentile, Michele Pizzuti, Robin Foa, M Breccia, E Abruzzese, F Castagnetti, M Bonifacio, D Gangemi, A Iurlo, L Luciano, A Gozzini, M Bocchia, D Luzi, A Maggi, N Sgherza, A Isidori, M Crugnola, P Pregno, AR ScortechiniI Capodanno

Risultato della ricerca: Contributo in rivistaArticolo in rivista

14 Citazioni (Scopus)

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32-72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.
Lingua originaleEnglish
pagine (da-a)1577-1580
Numero di pagine4
RivistaAnnals of Hematology
Stato di pubblicazionePubblicato - 2018

Keywords

  • inglese

Fingerprint

Entra nei temi di ricerca di 'Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.'. Insieme formano una fingerprint unica.

Cita questo